"We are very pleased that we have succeed to attract some of the world's leading cancer experts. Their solid experience from academia and industry together with their deep expertise in preclinical research will be a great asset to us, both in specific projects and in terms of the overall strategy. In parallel with the work of our newly formed scientific advisory board, our collaborations with the academy continue, including the collaboration with Associate Professor Julian Walfridsson at Karolinska Institutet,” said Erik Kinnman, CEO of Sprint Bioscience.

The Scientific Advisory Board consists of:

Gunilla Enblad – Professor of oncology at Uppsala University since 2013 and chief physician at Uppsala University Hospital. Her research areas include clinical and tumor biological studies of malignant lymphomas, as well as immunotherapy including clinical studies of CAR T cells. Since 2019, she is chairman of the Swedish CAR T-cell group and is also a scientific advisor to XNK-therapeutics and Elicera Therapeutics. She is a member of the board of the Cancer Foundation and the Department of Immunology, Genetics and Pathology at Uppsala University. Since 2017, she is also a member of the Royal Swedish Society of Science in Uppsala.

Robert J DeVita – Principal Consultant of RJD Med Chem and Drug Discovery Consulting LLC since 2013. He has over 30 years of drug discovery and development experience working in biotechnology, pharmaceutical industry, and academia. At Merck Research Laboratories, he was Director of Medicinal Chemistry and led 6 different programs that delivered drug candidates for further clinical development several which reached human clinical trials. He has also been Vice President, Chemistry at Agios, a company focused on early drug development in oncology. For the past 10 years, he has run a consulting company in medicinal chemistry and supported other client companies in all phases of drug development, including IP strategy and due diligence in connection with licensing deals. He is also a member of the Medicinal Chemistry Division of the American Chemical Society, serving in a variety of leadership roles.

Lewis C. Cantley – Professor at the Dana Farber Cancer institute. He is a cell biologist and biochemist who has made groundbreaking discoveries in the area of cancer metabolism. Among his most notable contributions is the discovery and study of the enzyme PI-3 kinase, which is important in diseases like cancer and diabetes. He was previously the Meyer Director and Professor of Cancer Biology at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine in New York City. He has also held positions as Professor at the Departments of Systems Biology and Medicine at Harvard Medical School and Director of Cancer Research at Beth Israel Deaconess Medical Center in Boston. Prof Cantley is also co-founder of several biotech companies focused on oncology, including Agios Pharmaceuticals, Petra Pharma and Volastra Therapeutics. In 2016, he was elected Chairman of the Board of the Hope Funds for Cancer Research and has over the years received several scientific awards for his research.